Patents by Inventor Xinjun Hou

Xinjun Hou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Papain-like protease (PLpro) inhibitors
    Publication number: 20240245673
    Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with PLpro activity and/or expression such as coronaviruses infections.
    Type: Application
    Filed: December 7, 2023
    Publication date: July 25, 2024
    Applicant: Pfizer Inc.
    Inventors: James Matthew Frick, Michelle Renee Garnsey, Brian Stephen Gerstenberger, Xinjun Hou, Magdalena Korczynska, Alpha Albert Lee, Luong Tien Nguyen, Usa Reilly, Matthew Christopher Robinson, Alexandria Paige Taylor, Thomas Reynold Vargo, Lei Zhang
  • HSD17B13 Inhibitors and/or Degraders
    Publication number: 20240238425
    Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 18, 2024
    Applicant: Pfizer Inc.
    Inventors: Jan Antoinette Cusi Romero Adams, Yotam Ashkenazi, Matthew Frank Brown, Jason Kenneth Dutra, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Yajing Lian, Deane Milford Nason, II, Steven Victor O'Neil, Amanda Brooke Pecora, Alistair Dean Richardson, Matthew Forrest Sammons, Yang Wang, Ann Sorrentino Wright, Jun Xiao, Lei Zhang, Liying Zhang
  • COMPOUNDS FOR THE ACTIVATION OF AMPK
    Publication number: 20240182468
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or peripheral vascular disease.
    Type: Application
    Filed: October 11, 2023
    Publication date: June 6, 2024
    Inventors: GARY ERIK ASPNES, CHRISTOPHER RYAN BUTLER, MATTHEW FRANK PAUL CALABRESE, KIMBERLY O'KEEFE CAMERON, JOHN MARION CURTO, MICHAEL ERIC GREEN, XINJUN HOU, SHENPING LIU, CHRISTOPHER LEE MCCLENDON, JOHN CHARLES MURRAY, ADVAITA PANCHAGNULA, COLIN RICHARD ROSE, KYLE THOMAS TARANTINO, MEIHUA MIKE TU, RAYOMAND JAL UNWALLA, JOSEPH SCOTT WARMUS, JUN XIAO, QINGYI YANG, LEI ZHANG
  • HSD17B13 INHIBITORS AND/OR DEGRADERS
    Publication number: 20240150334
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 9, 2024
    Applicant: Pfizer Inc.
    Inventors: Jan Antoinette Cusi Romero Adams, Bruce Michael Bechle, Jason Kenneth Dutra, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Deane Milford Nason, II, Steven Victor O'Neil, Danica Antonia Rankic, Yang Wang, Ann Sorrentino Wright, Lei Zhang, Liying Zhang, David James Edmonds
  • N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides
    Patent number: 10112958
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 30, 2018
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Patrick Robert Verhoest, Peter Justin Mikochik, John Charles Murray, Xinjun Hou
  • N-[2-(2-AMINO-6,6-DISUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL)-1,3-THIAZOL-4-YL] AMIDES
    Publication number: 20170305931
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Patrick Robert Verhoest, Peter Justin Mikochik, John Charles Murray, Xinjun Hou
  • N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides
    Patent number: 9751895
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 5, 2017
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Patrick Robert Verhoest, Peter Justin Mikochik, John Charles Murray, Xinjun Hou
  • N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides
    Publication number: 20170088558
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Patrick Robert Verhoest, Peter Justin Mikochik, John Charles Murray, Xinjun Hou
  • Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1)
    Publication number: 20050250742
    Abstract: Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.
    Type: Application
    Filed: March 3, 2004
    Publication date: November 10, 2005
    Inventors: Eleanor Dagostino, Liming Dong, Chuangxing Guo, Xinjun Hou, Stephen Margosiak
  • PIN1 peptidyl-prolyl isomerase polypeptides, their crystal structures, and use thereof for drug design
    Publication number: 20040171019
    Abstract: Polypeptides containing the PIN1 peptidyl-prolyl isomerase domain but not containing the PIN1 WW domain are described. Also described are crystal structures of these polypeptides, including the crystal structure of a PIN1 PPIase:ligand complex. The structure coordinate data derived from these crystals provides a three-dimensional description of the substrate-binding site of PIN1 peptidyl-prolyl isomerase useful in drug discovery and design for the identification and design of modulators of PIN1 peptidyl-prolyl isomerase activity.
    Type: Application
    Filed: December 19, 2003
    Publication date: September 2, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: David Matthews, Eleanor Dagostino, Rose Ann Ferre, Smita Gaur, Chuangxing Guo, Xinjun Hou, Stephen Margosiak, Barbara Mroczkowski, Grace Reiko Nakayama, Hans Parge, Jeff Zhu